STING orchestrates the neuronal inflammatory stress response in multiple sclerosis.

STING calcium signaling cell death excitotoxicity ferroptosis multiple sclerosis neurodegeneration neuroinflammation

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
07 Jun 2024
Historique:
received: 16 01 2024
revised: 08 04 2024
accepted: 16 05 2024
medline: 16 6 2024
pubmed: 16 6 2024
entrez: 15 6 2024
Statut: aheadofprint

Résumé

Inflammation-induced neurodegeneration is a defining feature of multiple sclerosis (MS), yet the underlying mechanisms remain unclear. By dissecting the neuronal inflammatory stress response, we discovered that neurons in MS and its mouse model induce the stimulator of interferon genes (STING). However, activation of neuronal STING requires its detachment from the stromal interaction molecule 1 (STIM1), a process triggered by glutamate excitotoxicity. This detachment initiates non-canonical STING signaling, which leads to autophagic degradation of glutathione peroxidase 4 (GPX4), essential for neuronal redox homeostasis and thereby inducing ferroptosis. Both genetic and pharmacological interventions that target STING in neurons protect against inflammation-induced neurodegeneration. Our findings position STING as a central regulator of the detrimental neuronal inflammatory stress response, integrating inflammation with glutamate signaling to cause neuronal cell death, and present it as a tractable target for treating neurodegeneration in MS.

Identifiants

pubmed: 38878778
pii: S0092-8674(24)00576-2
doi: 10.1016/j.cell.2024.05.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Marcel S Woo (MS)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Christina Mayer (C)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Lars Binkle-Ladisch (L)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Jana K Sonner (JK)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Sina C Rosenkranz (SC)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Artem Shaposhnykov (A)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Nicola Rothammer (N)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Volodymyr Tsvilovskyy (V)

Institute of Pharmacology, Heidelberg University, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.

Svenja M Lorenz (SM)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany.

Lukas Raich (L)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Lukas C Bal (LC)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Vanessa Vieira (V)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ingrid Wagner (I)

Department of Pathology and Immunology, Division of Clinical Pathology, Faculty of Medicine, University and University Hospital of Geneva, Geneva, Switzerland.

Simone Bauer (S)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Markus Glatzel (M)

Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Marcus Conrad (M)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany.

Doron Merkler (D)

Department of Pathology and Immunology, Division of Clinical Pathology, Faculty of Medicine, University and University Hospital of Geneva, Geneva, Switzerland.

Marc Freichel (M)

Institute of Pharmacology, Heidelberg University, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.

Manuel A Friese (MA)

Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: manuel.friese@zmnh.uni-hamburg.de.

Classifications MeSH